The pending Zyprexa class action lawsuit seeks over $700 million against the drug maker for failing to warn about side effects of Zyprexa like severe weight gain, diabetes, hyperglycemia and pancreatitis.
Zyprexa (olanzapine) is an atypical antipsychotic medication, which has generated sales of about $4.8 billion a year worldwide.
The plaintiffs will be allowed to pursue recovery of the money the drug maker made off of sales of the drug after a ruling by the Court of Appeal for Ontario denied Lilly’s attempt to limit their recovery to the damages suffered by the plaintiffs.
In the United States, as a result of similar claims filed by users who suffered diabetes and other injuries allegedly caused by Zyprexa, Lilly has already paid over $1.2 billion to settle about 30,000 lawsuits. They have also paid millions to settle state claims, and could face fines in excess of $1 billion following a Justice Department investigation into their marketing of the drug for unapproved uses.